Brokerages predict that Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) will report ($0.13) earnings per share for the current fiscal quarter, according to Zacks. Four analysts have made estimates for Arrowhead Pharmaceuticals’ earnings. The highest EPS estimate is ($0.07) and the lowest is ($0.22). Arrowhead Pharmaceuticals reported earnings per share of ($0.14) during the same quarter last year, which would indicate a positive year over year growth rate of 7.1%. The firm is scheduled to issue its next quarterly earnings report on Tuesday, December 11th.
On average, analysts expect that Arrowhead Pharmaceuticals will report full year earnings of ($0.64) per share for the current year, with EPS estimates ranging from ($0.76) to ($0.56). For the next fiscal year, analysts anticipate that the company will post earnings of ($0.59) per share, with EPS estimates ranging from ($0.90) to $0.30. Zacks’ earnings per share averages are a mean average based on a survey of sell-side analysts that cover Arrowhead Pharmaceuticals.
Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its quarterly earnings data on Tuesday, August 7th. The biotechnology company reported ($0.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.01. Arrowhead Pharmaceuticals had a negative return on equity of 59.39% and a negative net margin of 400.13%. The firm had revenue of $0.73 million during the quarter, compared to analyst estimates of $0.62 million.
Several research analysts have recently commented on the company. BidaskClub lowered Arrowhead Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Thursday, August 16th. Chardan Capital reiterated a “buy” rating and issued a $17.50 target price on shares of Arrowhead Pharmaceuticals in a research report on Monday, August 13th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $13.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, August 8th. Jefferies Financial Group reiterated a “buy” rating and issued a $20.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, August 8th. Finally, B. Riley lifted their target price on Arrowhead Pharmaceuticals from $12.00 to $18.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 8th. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $16.20.
NASDAQ ARWR traded down $1.21 during mid-day trading on Wednesday, reaching $14.10. 3,142,600 shares of the company’s stock traded hands, compared to its average volume of 1,801,784. Arrowhead Pharmaceuticals has a 1-year low of $2.65 and a 1-year high of $17.50. The company has a quick ratio of 8.69, a current ratio of 8.69 and a debt-to-equity ratio of 0.02. The firm has a market cap of $1.30 billion, a PE ratio of -30.00 and a beta of 1.91.
In related news, CEO Christopher Richard Anzalone sold 164,834 shares of the business’s stock in a transaction that occurred on Tuesday, September 4th. The stock was sold at an average price of $14.45, for a total transaction of $2,381,851.30. Following the completion of the transaction, the chief executive officer now owns 1,868,789 shares in the company, valued at approximately $27,004,001.05. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Kenneth Allen Myszkowski sold 20,000 shares of the business’s stock in a transaction that occurred on Tuesday, June 19th. The shares were sold at an average price of $14.01, for a total value of $280,200.00. Following the transaction, the chief financial officer now owns 330,815 shares of the company’s stock, valued at approximately $4,634,718.15. The disclosure for this sale can be found here. In the last quarter, insiders sold 284,834 shares of company stock valued at $4,107,051. Insiders own 4.60% of the company’s stock.
A number of large investors have recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp boosted its position in Arrowhead Pharmaceuticals by 341.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 340,244 shares of the biotechnology company’s stock valued at $4,628,000 after purchasing an additional 263,205 shares during the period. MetLife Investment Advisors LLC bought a new stake in Arrowhead Pharmaceuticals during the 2nd quarter valued at $557,000. Metropolitan Life Insurance Co. NY bought a new stake in Arrowhead Pharmaceuticals during the 2nd quarter valued at $393,000. Macquarie Group Ltd. bought a new stake in Arrowhead Pharmaceuticals during the 2nd quarter valued at $151,000. Finally, Cubist Systematic Strategies LLC bought a new stake in Arrowhead Pharmaceuticals during the 2nd quarter valued at $244,000. Institutional investors and hedge funds own 58.96% of the company’s stock.
Arrowhead Pharmaceuticals Company Profile
Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. Its pre-clinical stage medicines include ARO-HBV to treat chronic hepatitis B virus infection; ARO-AAT for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; ARO-APOC3 and ARO-ANG3 to treat hypertriglyceridemia; ARO-Lung1 for the treatment of an undisclosed pulmonary target; ARO-HIF2 to treat renal cell carcinoma; ARO-F12 for hereditary angioedema and thromboembolic disorders; and ARO-AMG1 for the treatment of an undisclosed genetically validated cardiovascular target.
Recommended Story: Investing in Dividend Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.